Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination

Author:  ["Jean D. Boyer","Kenneth E. Ugen","Bin Wang","Michael Agadjanyan","Lori Gilbert","Mark L. Bagarazzi","Michael Chattergoon","Patrice Frost","Ali Javadian","Williams V. Williams","Yosef Refaeli","Richard B. Ciccarelli","Daniel Mccallus","Leslie coney","David B. Weiner"]

Publication:  Nature Medicine

CITE.CC academic search helps you expand the influence of your papers.

Tags:     Medicine

Abstract

Novel approaches for the generation of more effective vaccines for HIV-1 are of significant importance. In this report we analyze the immunogenicity and efficacy of an HIV-1 DNA vaccine encoding env, rev and gag/pol in a chimpanzee model system. The immunized animals developed specific cellular and humoral immune responses. Animals were challenged with a heterologous chimpanzee titered stock of HIV-1 SF2 virus and followed for 48 weeks after challenge. Polymerase chain reaction coupled with reverse transcription (RT-PCR) results indicated infection in the control animal, whereas those animals vaccinated with the DNA constructs were protected from the establishment of infection. These studies serve as an important benchmark for the use of DNA vaccine technology for the production of protective immune responses.

Cite this article

Boyer, J., Ugen, K., Wang, B. et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med 3, 526–532 (1997). https://doi.org/10.1038/nm0597-526

View full text

>> Full Text:   Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination

Sunlight and skin cancer: Inhibition of p53 mutations in UV-irradiated mouse skin by sunscreens

Human leptin levels are pulsatile and inversely related to pituitary–ardenal function